Human papillomavirus E6 and E7 proteins (HPV E6/E7)

Cervical cancer-associated antigens are a group of proteins specifically expressed or significantly overexpressed in cervical malignancies, serving as primary targets for immunotherapy and diagnostic monitoring [4, 17]. The most critical members are the Human Papillomavirus (HPV) E6 and E7 oncoproteins, which are essential for the initiation and maintenance of the malignant state in HPV-positive cancers [3, 18]. These viral proteins drive oncogenesis by degrading or inactivating key host tumor suppressors, such as p53 and Retinoblastoma (Rb), leading to genomic instability and uncontrolled cell growth [17, 18]. Another significant antigen is the Squamous Cell Carcinoma Antigen (SCCA), also known as TA-4, which is a member of the serpin family and is widely used as a clinical biomarker for disease recurrence and treatment response [1, 15]. Therapeutic interventions targeting these antigens focus on eliciting a robust, tumor-specific immune response [3, 14]. Numerous therapeutic vaccines, including DNA-based (e.g., VGX-3100), peptide-based (e.g., ISA101), and live-attenuated bacterial vectors (e.g., ADXS11-001), are in clinical development to induce CD8+ T-cell-mediated killing of cancer cells [3, 14]. Additionally, advanced modalities like TCR-engineered T cells and immune-stimulating fusion proteins are being explored to enhance the efficacy of targeting these antigens [18, 26]. While these targets offer high specificity, challenges such as the immunosuppressive tumor microenvironment and the need for effective delivery systems remain central to the development of successful therapies [3, 28].

Other names

Cervical cancer-associated antigensHPV oncoproteinsSquamous cell carcinoma antigenSCCATA-4Tumor-associated antigen 4

Therapeutic vaccines and adoptive T-cell therapies targeting these antigens are designed to stimulate the host's immune system, particularly CD8+ cytotoxic T lymphocytes, to recognize and eliminate cells expressing the viral oncoproteins E6 and E7 [3, 14, 18]. These therapies often utilize DNA plasmids, peptide fragments, or viral vectors to deliver the antigenic sequences, thereby breaking immune tolerance and promoting tumor regression [3, 14].